{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:08:36Z","timestamp":1785550116210,"version":"3.56.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40266-022-00961-y","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:02:46Z","timestamp":1658361766000},"page":"715-727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients\u2014A BioCAPTURE Registry Study"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9874-4670","authenticated-orcid":false,"given":"E. L. M.","family":"ter Haar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-353X","authenticated-orcid":false,"given":"S. E.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3642-2673","authenticated-orcid":false,"given":"J. M. P. A.","family":"van den Reek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0191-3293","authenticated-orcid":false,"given":"M. E.","family":"Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1424-5722","authenticated-orcid":false,"given":"M. D.","family":"Njoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7311-7213","authenticated-orcid":false,"given":"P. M.","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. N.","family":"Kop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5395-5925","authenticated-orcid":false,"given":"S. R. P.","family":"Dodemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. E. M.","family":"K\u00f6rver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7874-1165","authenticated-orcid":false,"given":"A. L. A.","family":"Kuijpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Lindhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2378-3741","authenticated-orcid":false,"given":"R. A.","family":"Tupker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4930-4107","authenticated-orcid":false,"given":"J. M.","family":"Mommers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3851-1407","authenticated-orcid":false,"given":"M. A. M.","family":"Berends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7823-8380","authenticated-orcid":false,"given":"M. I. A.","family":"Koetsier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-6993","authenticated-orcid":false,"given":"M. S.","family":"de Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6265-3830","authenticated-orcid":false,"given":"M. B.","family":"Visch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7267-7825","authenticated-orcid":false,"given":"W. P.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6619-0853","authenticated-orcid":false,"given":"P. P. M.","family":"van L\u00fcmig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"Kleinpenning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2694-6059","authenticated-orcid":false,"given":"S. F. K.","family":"Lubeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3872-5704","authenticated-orcid":false,"given":"E. M. G. J.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"issue":"2","key":"961_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, Identification, Management of P, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377\u201385. https:\/\/doi.org\/10.1038\/jid.2012.339.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"961_CR2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdv.13854","volume":"31","author":"IM Michalek","year":"2017","unstructured":"Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205\u201312. https:\/\/doi.org\/10.1111\/jdv.13854.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"961_CR3","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1001\/jamadermatol.2020.2311","volume":"156","author":"MEC van Winden","year":"2020","unstructured":"van Winden MEC, van der Schoot LS, van de L\u2019Isle AM, van Vugt LJ, van den Reek J, van de Kerkhof PCM, et al. Effectiveness and safety of systemic therapy for psoriasis in older adults: a systematic review. JAMA Dermatol. 2020;156(11):1229\u201339. https:\/\/doi.org\/10.1001\/jamadermatol.2020.2311.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"961_CR4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jaad.2019.07.079","volume":"83","author":"MJ Schaap","year":"2020","unstructured":"Schaap MJ, van Winden MEC, Seyger MMB, de Jong EMGJ, Lubeek SFK. Representation of older adults in randomized controlled trials on systemic treatment in plaque psoriasis: a systematic review. J Am Acad Dermatol. 2020;83(2):412\u201324. https:\/\/doi.org\/10.1016\/j.jaad.2019.07.079.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"961_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1001\/archdermatol.2011.2768","volume":"148","author":"I Garcia-Doval","year":"2012","unstructured":"Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Dauden E, Sanchez-Carazo JL, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol. 2012;148(4):463\u201370.","journal-title":"Arch Dermatol"},{"issue":"3","key":"961_CR6","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/bjd.14331","volume":"174","author":"K Geale","year":"2016","unstructured":"Geale K, Henriksson M, Schmitt-Egenolf M. Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics. Br J Dermatol. 2016;174(3):579\u201387. https:\/\/doi.org\/10.1111\/bjd.14331.","journal-title":"Br J Dermatol"},{"issue":"2","key":"961_CR7","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/1203475419897578","volume":"24","author":"VK Sandhu","year":"2020","unstructured":"Sandhu VK, Ighani A, Fleming P, Lynde CW. Biologic treatment in elderly patients with psoriasis: a systematic review. J Cutan Med Surg. 2020;24(2):174\u201386. https:\/\/doi.org\/10.1177\/1203475419897578.","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"961_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jaad.2010.05.014","volume":"65","author":"IS Grozdev","year":"2011","unstructured":"Grozdev IS, Van Voorhees AS, Gottlieb AB, Hsu S, Lebwohl MG, Bebo BF Jr, et al. Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2011;65(3):537\u201345. https:\/\/doi.org\/10.1016\/j.jaad.2010.05.014.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"961_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis"},{"issue":"12","key":"961_CR10","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","volume":"57","author":"V Sundararajan","year":"2004","unstructured":"Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57(12):1288\u201394. https:\/\/doi.org\/10.1016\/j.jclinepi.2004.03.012.","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"961_CR11","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","volume":"4","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296. https:\/\/doi.org\/10.1371\/journal.pmed.0040296.","journal-title":"PLoS Med"},{"key":"961_CR12","unstructured":"European Medicines Agency. ICH E6 (R2) good clinical practice. European Medicines Agency; 2016 [cited 12 Jan 2022]."},{"issue":"1","key":"961_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jaad.2012.05.040","volume":"68","author":"PP van L\u00fcmig","year":"2013","unstructured":"van L\u00fcmig PP, Driessen RJ, Kievit W, Boezeman JB, van de Kerkhof PC, de Jong EM. Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice. J Am Acad Dermatol. 2013;68(1):57\u201363. https:\/\/doi.org\/10.1016\/j.jaad.2012.05.040.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"961_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2340\/00015555-1719","volume":"94","author":"S Piaserico","year":"2014","unstructured":"Piaserico S, Conti A, Lo Console F, De Simone C, Prestinari F, Mazzotta A, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2014;94(3):293\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"961_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40266-014-0156-6","volume":"31","author":"N Balato","year":"2014","unstructured":"Balato N, Patruno C, Napolitano M, Patr\u00ec A, Ayala F, Scarpa R. Managing moderate-to-severe psoriasis in the elderly. Drugs Aging. 2014;31(4):233\u20138. https:\/\/doi.org\/10.1007\/s40266-014-0156-6.","journal-title":"Drugs Aging"},{"issue":"1","key":"961_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/jdv.12850","volume":"30","author":"C Phan","year":"2016","unstructured":"Phan C, Sigal ML, Esteve E, Reguiai Z, Barthelemy H, Beneton N, et al. Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis. J Eur Acad Dermatol Venereol. 2016;30(1):78\u201382. https:\/\/doi.org\/10.1111\/jdv.12850.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7172","key":"961_CR17","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1136\/bmj.317.7172.1572","volume":"317","author":"JM Bland","year":"1998","unstructured":"Bland JM, Altman DG. Survival probabilities (the Kaplan\u2013Meier method). BMJ. 1998;317(7172):1572. https:\/\/doi.org\/10.1136\/bmj.317.7172.1572.","journal-title":"BMJ"},{"issue":"5","key":"961_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/jid.2014.132","volume":"134","author":"M Wakkee","year":"2014","unstructured":"Wakkee M, Hollestein LM, Nijsten T. Multivariable analysis. J Invest Dermatol. 2014;134(5):1\u20135. https:\/\/doi.org\/10.1038\/jid.2014.132.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"961_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/jid.2015.171","volume":"135","author":"J van den Reek","year":"2015","unstructured":"van den Reek J, Kievit W, Gniadecki R, Goeman JJ, Zweegers J, van de Kerkhof PCM, et al. Drug survival studies in dermatology:principles, purposes, and pitfalls. J Invest Dermatol. 2015;135(7):1\u20135. https:\/\/doi.org\/10.1038\/jid.2015.171.","journal-title":"J Invest Dermatol"},{"key":"961_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/life11121348","volume":"11","author":"CG Osuna","year":"2021","unstructured":"Osuna CG, Garc\u00eda SR, Mart\u00edn JC, Jim\u00e9nez VG, L\u00f3pez FV, Santos-Juanes J. Use of biological treatments in elderly patients with skin psoriasis in the real world. Life (Basel). 2021;11:12. https:\/\/doi.org\/10.3390\/life11121348.","journal-title":"Life (Basel)"},{"issue":"4","key":"961_CR21","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/bjd.19665","volume":"184","author":"MEC van Winden","year":"2021","unstructured":"van Winden MEC, Ter Haar ELM, Groenewoud JMM, van de Kerkhof PCM, de Jong E, Lubeek SFK. Quality of life, treatment goals, preferences and satisfaction in older adults with psoriasis: a patient survey comparing age groups. Br J Dermatol. 2021;184(4):759\u201362. https:\/\/doi.org\/10.1111\/bjd.19665.","journal-title":"Br J Dermatol"},{"issue":"4","key":"961_CR22","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/jdv.15324","volume":"33","author":"JT Maul","year":"2019","unstructured":"Maul JT, Navarini AA, Sommer R, Anzengruber F, Sorbe C, Mrowietz U, et al. Gender and age significantly determine patient needs and treatment goals in psoriasis\u2014a lesson for practice. J Eur Acad Dermatol Venereol. 2019;33(4):700\u20138. https:\/\/doi.org\/10.1111\/jdv.15324.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"961_CR23","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/jamainternmed.2018.4720","volume":"178","author":"E Reeve","year":"2018","unstructured":"Reeve E, Wolff JL, Skehan M, Bayliss EA, Hilmer SN, Boyd CM. Assessment of attitudes toward deprescribing in older medicare beneficiaries in the United States. JAMA Intern Med. 2018;178(12):1673\u201380. https:\/\/doi.org\/10.1001\/jamainternmed.2018.4720.","journal-title":"JAMA Intern Med"},{"issue":"10","key":"961_CR24","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1634\/theoncologist.2014-0180","volume":"19","author":"S Sattar","year":"2014","unstructured":"Sattar S, Alibhai SM, Wildiers H, Puts MT. How to implement a geriatric assessment in your clinical practice. Oncologist. 2014;19(10):1056\u201368. https:\/\/doi.org\/10.1634\/theoncologist.2014-0180.","journal-title":"Oncologist"},{"issue":"14","key":"961_CR25","doi-asserted-by":"publisher","first-page":"adv00215","DOI":"10.2340\/00015555-3569","volume":"100","author":"MEC van Winden","year":"2020","unstructured":"van Winden MEC, ter Haar ELM, Groenewoud HMM, van de Kerkhof PCM, de Jong E, Lubeek SFK. Disease and treatment characteristics in geriatric psoriasis: a patient survey comparing age groups. Acta Derm Venereol. 2020;100(14):adv00215. https:\/\/doi.org\/10.2340\/00015555-3569.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"961_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bjd.12039","volume":"168","author":"RJ Thorneloe","year":"2013","unstructured":"Thorneloe RJ, Bundy C, Griffiths CE, Ashcroft DM, Cordingley L. Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol. 2013;168(1):20\u201331. https:\/\/doi.org\/10.1111\/bjd.12039.","journal-title":"Br J Dermatol"},{"issue":"1","key":"961_CR27","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1111\/bjd.15856","volume":"178","author":"R Hambly","year":"2018","unstructured":"Hambly R, Kelly A, Gilhooley E, Nic Dhonncha E, Murad A, Hughes R, et al. Medication adherence among patients with psoriasis on traditional systemic and biologics treatment. Br J Dermatol. 2018;178(1):e46\u20138. https:\/\/doi.org\/10.1111\/bjd.15856.","journal-title":"Br J Dermatol"},{"issue":"1","key":"961_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2042098615615472","volume":"7","author":"AH Lavan","year":"2016","unstructured":"Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf. 2016;7(1):11\u201322. https:\/\/doi.org\/10.1177\/2042098615615472.","journal-title":"Ther Adv Drug Saf."},{"issue":"4","key":"961_CR29","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000345623","volume":"225","author":"M Esposito","year":"2012","unstructured":"Esposito M, Giunta A, Mazzotta A, Zangrilli A, Babino G, Bavetta M, et al. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology (Basel, Switzerland). 2012;225(4):312\u20139. https:\/\/doi.org\/10.1159\/000345623.","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"2","key":"961_CR30","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1177\/039463200902200218","volume":"22","author":"A Migliore","year":"2009","unstructured":"Migliore A, Bizzi E, Lagan\u00e0 B, Altomonte L, Zaccari G, Granata M, et al. The safety of anti-TNF agents in the elderly. Int J Immunopathol Pharmacol. 2009;22(2):415\u201326. https:\/\/doi.org\/10.1177\/039463200902200218.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"2","key":"961_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40266-018-0520-z","volume":"35","author":"A K\u00f6rber","year":"2018","unstructured":"K\u00f6rber A, Papavassilis C, Bhosekar V, Reinhardt M. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies. Drugs Aging. 2018;35(2):135\u201344. https:\/\/doi.org\/10.1007\/s40266-018-0520-z.","journal-title":"Drugs Aging"},{"issue":"5","key":"961_CR32","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jaad.2017.07.013","volume":"77","author":"D Fiorentino","year":"2017","unstructured":"Fiorentino D, Ho V, Lebwohl MG, Leite L, Hopkins L, Galindo C, et al. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol. 2017;77(5):845-54.e5. https:\/\/doi.org\/10.1016\/j.jaad.2017.07.013.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"961_CR33","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaad.2009.09.040","volume":"63","author":"A Menter","year":"2010","unstructured":"Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010;63(3):448\u201356. https:\/\/doi.org\/10.1016\/j.jaad.2009.09.040.","journal-title":"J Am Acad Dermatol"},{"key":"961_CR34","doi-asserted-by":"crossref","unstructured":"Chimenti MS, Esposito M, Giunta A, Bavetta M, Rinaldi M, Chimenti S, et al. Efficacy and safety of subcutaneous anti-TNF alpha, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: An observational long term study. Annals of the Rheumatic Disease Conference: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR. 2012;71.","DOI":"10.1136\/annrheumdis-2012-eular.942"},{"issue":"3 Suppl 2","key":"961_CR35","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1016\/j.jaad.2005.11.1088","volume":"54","author":"K Gordon","year":"2006","unstructured":"Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol. 2006;54(3 Suppl 2):S101\u201311. https:\/\/doi.org\/10.1016\/j.jaad.2005.11.1088.","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"961_CR36","doi-asserted-by":"publisher","first-page":"adv00316","DOI":"10.2340\/00015555-3678","volume":"100","author":"C Phan","year":"2020","unstructured":"Phan C, Beneton N, Delaunay J, Reguiai Z, Boulard C, Fougerousse AC, et al. Effectiveness and safety of anti-interleukin-17 therapies in elderly patients with psoriasis. Acta Derm Venereol. 2020;100(18):adv00316. https:\/\/doi.org\/10.2340\/00015555-3678.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"961_CR37","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/ced.12850","volume":"41","author":"M Megna","year":"2016","unstructured":"Megna M, Napolitano M, Balato N, Monfrecola G, Villani A, Ayala F, et al. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol. 2016;41(5):564\u20136. https:\/\/doi.org\/10.1111\/ced.12850.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"961_CR38","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/ced.14979","volume":"47","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin Exp Dermatol. 2022;47(3):561\u20137. https:\/\/doi.org\/10.1111\/ced.14979.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"961_CR39","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/jdv.12688","volume":"29","author":"C Medina","year":"2015","unstructured":"Medina C, Carretero G, Ferrandiz C, Dauden E, Vanaclocha F, Gomez-Garcia FJ, et al. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry. J Eur Acad Dermatol Venereol. 2015;29(5):858\u201364. https:\/\/doi.org\/10.1111\/jdv.12688.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-022-00961-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-022-00961-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-022-00961-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T06:02:23Z","timestamp":1662703343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-022-00961-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["961"],"URL":"https:\/\/doi.org\/10.1007\/s40266-022-00961-y","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]},"assertion":[{"value":"8 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E.L.M. ter Haar has carried out investigator-initiated research with financial support from Almirall and has carried out clinical trials for Novartis. All funding is not personal but goes to the independent research fund of the Department of Dermatology, Radboud University Medical Center Nijmegen (Radboudumc), The Netherlands. S.E. Thomas carries out clinical trials for Janssen and Novartis. All funding is not personal but goes to the independent research fund of the Department of Dermatology, Radboud University Medical Center Nijmegen, The Netherlands. M.E. Otero has acted as a consultant for Eli Lilly. P.P.M. van L\u00fcmig has received research funding from Wyeth; has carried out clinical trials for Abbott and Janssen-Cilag; has received speaking and consulting fees from Wyeth and Schering-Plough; has received reimbursement for attending a symposium from Schering-Plough and Pfizer; and has attended advisory boards for Abbvie, Leo Pharma, Novartis and UCB. W.P. Arnold has been a consultant, advisory board member, and\/or speaker for AbbVie and UCB. S.R.P. Dodemont has attended advisory boards for Abbvie, Janssen and Leo Pharma, and has received a congress fee from Abbvie. M.S. de Bruin-Weller has been a consultant, advisory board member, and\/or speaker for AbbVie, Almirall, Arena, Aslan, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron, and Sanofi-Genzyme. R.A. Tupker has attended advisory boards for Leo Pharma, UCB Pharma, and Eli Lilly Netherlands. E.M.G.J. de Jong has received research grants for the independent research fund of the Department of Dermatology, Radboud University Medical Center Nijmegen, The Netherlands, from AbbVie, BMS, Janssen Pharmaceutica, Leo Pharma, Novartis, and UCB for research on psoriasis; has acted as a consultant and\/or paid speaker for, and\/or participated in research sponsored by, companies that manufacture drugs used for the treatment of psoriasis or eczema, including AbbVie, Amgen, Almirall, Celgene, Galapagos, Janssen Pharmaceutica, Lilly, Novartis, Leo Pharma, Sanofi and UCB. All funding is not personal but goes to the independent research fund of the Department of Dermatology, Radboud University Medical Center Nijmegen, The Netherlands. J.M.P.A. van den Reek has carried out clinical trials for AbbVie, Celgene and Janssen; has received speaking fees\/attended advisory boards from AbbVie, Janssen, BMS, Almirall, LEO Pharma, and Eli Lilly; and has received reimbursement for attending a symposium from Janssen, Pfizer, Celgene, and AbbVie. All funding is not personal but goes to the independent research fund of the Department of Dermatology, Radboud University Medical Center Nijmegen, The Netherlands. S.F.K. Lubeek has received research grants for investigator-initiated research by Almirall, and has acted as a consultant and\/or paid speaker for Janssen, LEO Pharma, Almirall, Sanofi Genzyme, and Sunpharma. All funding is not personal but goes to the independent research fund of the Department of Dermatology, Radboud University Medical Centre Nijmegen, The Netherlands. M.D. Njoo, P.M. Ossenkoppele, E.N. Kop, J.E.M. K\u00f6rver, A.L.A. Kuijpers, R.J. Lindhout, J.M. Mommers, M.A.M. Berends, M.I.A. Koetsier, M.B. Visch, and M.M. Kleinpenning have no conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"BioCAPTURE was funded by the University Medical Center St Radboud Foundation. This foundation received funding from Pfizer, Janssen, Novartis, LEO Pharma, AbbVie, Almirall, Eli Lilly, and UCB. All decisions regarding the design and execution of this study, data collection, data management, data analysis, interpretation of the data, manuscript preparation, manuscript review, or manuscript approval were made independently from industrial contributions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ethical review and approval were waived for this study in consultation with our regional Medical Ethics Committee due to the non-interventional design of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was not necessary due to the non-interventional design of this study; however, written informed consent is obtained from every patient included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable (see the Consent to participate section).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are not publicly available as participants of this study did not agree for their data to be shared publicly.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: ELMtH, SET, JMPAvdR, EMGJdJ and SFKL. Methodology: ELMtH, SET, JMPAvdR, EMGJdJ and SFKL. Software: ELMtH, SET and JMPAvdR. Validation: JMPAvdR, EMGJdJ and SFKL. Formal analysis: ELMtH, SET and JMPAvdReek. Investigation: ELMtH and SET. Resources: MEO, MDN, PMO, ENK, SD, JEMK, ALAK, RJL, RAT, JMM, MAMB, MIAK, MSdB, BV, WPA, PPvL, MMK. Data curation: MEO, ELMtH and SET. Writing\u2014original draft preparation: ELMtH and SET. Writing\u2014review and editing: JMPAvdR, EMGJdJ and SFKL, MEO, MDN, PMO, ENK, SD, JEMK, ALAK, RJL, RAT, JMM, MAMB, MIAK, MSdB, BV, WPA, PPvL, MMK. Visualization: ELMtH, SET. Supervision: JMPAvdR, EMGJdJ and SFKL. Project administration: JMPAvdR, EMGJdJ and SFKL. Funding acquisition: MEO, JMPAvdR, EMGJdJ.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}